Patrick Daly

DocwireNews

In this analysis, Francesco Passamonti and colleagues assessed 32 patients (median age, 69) who received NAV+RUX. The population of interest all had primary or secondary MF with splenomegaly and had not received any prior treatment of JAK-3 therapy, nor had they ever taken bromodomain and extraterminal motif (BET) inhibitors. The primary outcome of interest was spleen volume reduction of 35% or more from baseline after 24 weeks.&nbsp; The secondary endpoints were at least a 50% reduction in total symptom score, bone marrow (BM) fibrosis reduction, and anemia response.According to the results, over half of patients (52%) achieved spleen reduction, meeting the primary endpoint. While 97% of patients reported least one adverse event (AE), only 19% exhibited serious AEs. The most common Grade &ge;3 AEs were anemia (34%), thrombocytopenia (31%), and neutropenia (19%), the researchers noted.In conclusion, the researchers stated that the &ldquo;combination of NAV+RUX was well tolerated and demonstrated early and robust reductions in spleen volume, anemia, and BM fibrosis in pts without prior JAK-2 inhibitor exposure.&rdquo;

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Effective Treatment Combination in JAK Inhibitor-Naive Patients With Myelofibrosis

ASCO 2022

In this analysis, Francesco Passamonti and colleagues assessed 32 patients (median age, 69) who received NAV+RUX. The population of interest all had primary or secondary MF ...

Effective Treatment Combination in JAK Inhibitor-naive Patients with Myelofibrosis

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe